Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
2.
Melanoma Res ; 26(5): 487-91, 2016 10.
Article in English | MEDLINE | ID: mdl-27261949

ABSTRACT

Cutaneous squamous cell carcinoma (cSCC) is a frequent side-effect of vemurafenib treatment. The main aim of this study was to identify the clinical risk factors associated with the development of cSCC in melanoma patients treated with vemurafenib. We carried out a retrospective study, including 63 consecutive melanoma patients treated with vemurafenib for BRAF-mutant metastatic melanoma in an oncodermatological department. Clinical and follow-up data were collected and analysed, and a comparison of the subgroups who did and did not develop cSCC was performed. A total of 42.9% of patients (n=27) treated with vemurafenib developed one or more cSCC. Patients with cSCC were significantly older (P=0.01). Clear eyes were also associated with a higher risk of developing cSCC (odds ratio=3.50; 95% confidence interval: 1.08-12.43). Three patients developed cSCC more than 1 year after the initiation of treatment (12, 16 and 18 months, respectively). Clinicians should be vigilant in older patients undergoing vemurafenib therapy as well as patients with clear eyes as they seem to be at increased risk of developing cSCC, even late after the initiation of treatment.


Subject(s)
Adrenergic alpha-Agonists/adverse effects , Carcinoma, Squamous Cell/etiology , Indoles/adverse effects , Melanoma/complications , Naphazoline/adverse effects , Skin Neoplasms/etiology , Sulfonamides/adverse effects , Age Factors , Carcinoma, Squamous Cell/pathology , Female , Humans , Indoles/pharmacology , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Retrospective Studies , Risk Factors , Skin Neoplasms/pathology , Sulfonamides/pharmacology , Vemurafenib
3.
Dermatology ; 226(2): 119-23, 2013.
Article in English | MEDLINE | ID: mdl-23548825

ABSTRACT

BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE) can be induced by numerous drugs. We report 3 cases of SCLE induced by proton pump inhibitors (PPIs). OBJECTIVE: To highlight a rare cutaneous side effect induced by a frequently prescribed drug such as a PPI. CASE REPORTS: Case 1 was a 30-year-old man who developed multiple annular plaques over the trunk and lower limbs 1 month after the initiation of pantoprazole. Antinuclear antibodies (ANA) were positive with anti-Ro/SSA and anti-La/SSB antibodies, and histology confirmed the diagnosis. Clinical improvement was achieved 8 weeks after the discontinuation of pantoprazole and the introduction of a treatment combining topical steroids and hydroxychloroquine. Lesions relapsed when pantoprazole was accidentally rechallenged. The second case was a 31-year-old woman, 28 weeks pregnant, who presented erythematous annular plaques over the trunk 7 weeks after starting esomeprazole. ANA and anti-Ro/SSA antibodies were positive, and the histology was compatible with SCLE. Fetal ultrasound was normal. She was treated with topical and oral steroids and hydroxychloroquine. Clinical improvement was achieved 4 weeks after the discontinuation of esomeprazole. The third case was a 57-year-old woman with systemic erythematosus lupus presenting annular and psoriasiform lesions on the trunk for 15 months. She was treated successively with hydroxychloroquine, azathioprine, mycophenolate mofetil and methotrexate with prednisone. A review of her drug history revealed the introduction of omeprazole a few weeks before the first appearance of skin lesions and omeprazole was contraindicated. CONCLUSION: SCLE should systematically be suspected in case of eruption after the introduction of PPI. The risk of fetal cardiac complications is important in pregnant women.


Subject(s)
Lupus Erythematosus, Cutaneous/chemically induced , Proton Pump Inhibitors/adverse effects , 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects , Adult , Esomeprazole/adverse effects , Female , Humans , Lupus Erythematosus, Cutaneous/pathology , Male , Middle Aged , Omeprazole/adverse effects , Pantoprazole
4.
J Am Acad Dermatol ; 68(2): 313-31, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22695100

ABSTRACT

BACKGROUND: Treatment guidelines are lacking for classic Kaposi sarcoma. OBJECTIVE: We sought to review the evidence on efficacy of treatments for classic Kaposi sarcoma. METHODS: Articles published in English or French in MEDLINE, Trip, Cochrane Library, and Pascal databases from 1980 to December 2010 were screened. Studies reporting at least 5 patients treated for histologically confirmed classic Kaposi sarcoma were selected. Primary outcome was a decrease in the number or size of lesions or of lymphedema. We reviewed 26 articles matching the inclusion criteria for methodologic quality, classifying them according to World Health Organization criteria. RESULTS: The percentage of patients with a 50% or greater decrease in lesions was 71% to 100% for pegylated liposomal doxorubicin, 58% to 90% for vinca-alkaloids, 74% to 76% for etoposide, 93% to 100% for taxanes, 100% for gemcitabine, 97% for the combination of vinblastine and bleomycin, 71% to 100% for interferon alfa-2, 43% for thalidomide, and 12% for indinavir. For local treatments, a decrease of 50% or greater was achieved in 62% of lesions for intralesional vincristine, 50% to 90% for intralesional interferon alfa-2, 56% for imiquimod, and 25% for nicotine patches. A complete response was attained in 60% to 93% of lesions with radiotherapy. LIMITATIONS: Eligible trials were of poor quality. The lack of standardized classification of disease activity and clinical outcomes precluded the comparison of studies. CONCLUSION: The evidence for efficacy of any particular intervention is of low quality and does not support recommending any particular therapeutic strategy. Further studies are required and it will be important to standardize the assessment of disease activity and clinical response.


Subject(s)
Sarcoma, Kaposi/drug therapy , Skin Neoplasms/drug therapy , Doxorubicin/analogs & derivatives , Doxorubicin/therapeutic use , Etoposide/therapeutic use , Female , Humans , Interferon-alpha/therapeutic use , Male , Polyethylene Glycols/therapeutic use , Taxoids/therapeutic use , Vinca Alkaloids/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...